ZIVO Bioscience, Inc. (ZIVO) Fair Value 2026

ZIVO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.4 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (22/100)

Quick Summary — As of 2026-08-27, ZIVO Bioscience, Inc. (ZIVO) trades at $4.27. QOC: 5.4/10. Value Trap Risk: 22/100 (SAFE). 0/13 models active.

Key Facts

Ticker
ZIVO
Price
$4.27
Quality Score
5.4/10
Value Trap Risk
22/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give ZIVO?

0 Intrinsic Value Models vs. Current Price ($4.27)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is ZIVO Bioscience, Inc. (ZIVO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ZIVO Bioscience, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ZIVO?

0 of 13 models are currently active for ZIVO. See which stocks rank higher →

How Does ZIVO Rank in Biotechnology?

Among 620 Biotechnology stocks, ZIVO ranks #244 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

ZIVO Bioscience, Inc.'s positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including breakthrough therapy designations — shape both the opportunity set and risk profile.

Is ZIVO a Value Trap?

CirclFi's Value Trap algorithm assigns ZIVO a score of 22/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for ZIVO Bioscience, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, ZIVO Bioscience, Inc. earns a quality score of 5.4/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ZIVO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ZIVO Bioscience, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

JANXJanux Therapeutics, Inc.QOC 5.4PHVSPharvaris N.V.QOC 5.4ANEBAnebulo Pharmaceuticals, Inc.QOC 5.4VSTMVerastem, Inc.QOC 5.4PULMPulmatrix, Inc.QOC 5.4APLMApollomics, Inc.QOC 5.3CLRBCellectar Biosciences, Inc.QOC 4.7CTXRCitius Pharmaceuticals, Inc.QOC 3.7SNDXSyndax Pharmaceuticals, Inc.QOC 6.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: JANX · PHVS · ANEB · VSTM · PULM · APLM · CLRB · CTXR · SNDX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ZIVO?

7 companies across all industries closest to ZIVO’s Quality of Company score of 5.4/10.

CORZCore Scientific, Inc.QOC 5.4KDKKodiak AI, Inc.QOC 5.4BRCBBlack Rock Coffee Bar, Inc.QOC 5.4QSIQuantum-Si incorporatedQOC 5.4AHTAshford Hospitality Trust, Inc.QOC 5.4NYCAmerican Strategic Investment Co.QOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CORZ · KDK · BRCB · QSI · AHT · NYC · NVDA

Where Does ZIVO Sit in CirclFi's Biotechnology Rankings?

ZIVO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About ZIVO Bioscience, Inc.’s Valuation?

What is ZIVO Bioscience, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ZIVO Bioscience, Inc. (ZIVO). The Quality of Company score is 5.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ZIVO overvalued or undervalued right now?

At $4.27, 0 of 0 active models suggest ZIVO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits ZIVO Bioscience, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.4 mean for ZIVO?

ZIVO Bioscience, Inc.'s QOC of 5.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ZIVO?

CirclFi analyzes ZIVO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ZIVO a value trap in 2026?

ZIVO Bioscience, Inc.'s Value Trap score is 22/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ZIVO Bioscience, Inc. (ZIVO) a Quality of Company score of 5.4/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ZIVO/ · Methodology
Primary sources for this ZIVO valuation
  • Financial statements: ZIVO Bioscience, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001101026) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ZIVO as of ; valuations recomputed .